Immune Mediated Necrotizing Myopathy: Where do we Stand?

Author(s): Abdel Gaffar A Mohammed*, Ayanda Gcelu, Farzana Moosajee, Stella Botha, Asgar Ali Kalla.

Journal Name: Current Rheumatology Reviews

Volume 15 , Issue 1 , 2019

Submit Manuscript
Submit Proposal

Abstract:

Immune-mediated necrotizing myopathies (IMNMs) are a group of acquired autoimmune muscle disorders which are characterized by proximal muscle weakness, high levels of creatinine kinase, and myopathic findings on electromyogram (EMG). Muscle biopsy in IMNM differentiates it from the other subgroups of Idiopathic Inflammatory Myositis (IIM) by the presence of myofibre necrosis and prominent regeneration without substantial lymphocytic inflammatory infiltrates. Anti-signal recognition particle (SRP) and anti-3hydroxy-3 methylglutarylcoenzyme A reductase (HMGCR) autoantibodies were found in two-thirds of IMNM patients. In terms of treatment, IMNM is more resistant to conventional immunosuppressive treatment, therefore, other modalities of treatment such as Intravenous Immunoglobulin (IVIG) and rituximab are often required.

Keywords: Myopathy, anti-SRP, myositis, anti-HMGCR, IMNMs, EMG, IVIG.

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 15
ISSUE: 1
Year: 2019
Page: [23 - 26]
Pages: 4
DOI: 10.2174/1573397114666180406101850
Price: $58

Article Metrics

PDF: 41
HTML: 2